Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

Active, not recruitingOBSERVATIONAL
Enrollment

221

Participants

Timeline

Start Date

September 14, 2020

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2030

Conditions
CardiotoxicityLung Cancer Stage IIILung Cancer Stage IIRadiation Toxicity
Interventions
OTHER

Chemoradiation

Patients will be treated with definitive concurrent chemoradiation with curative intent as determined by their medical and radiation oncologists. We will consider timing of initiation and discontinuation, type, and cumulative dose of platinum based chemotherapy. We will also consider dose, duration, and type of immunotherapy. Radiation therapy will be delivered via proton or proton therapy. Our primary radiation therapy dose-volume exposures are whole heart volumetric dose. As secondary exposures, we will comprehensively define radiation therapy dose parameters to the right ventricle, entire left ventricle, left ventricle segments, coronary arteries, and mean heart dose.

Trial Locations (8)

17601

Lancaster General Hospital, Lancaster

19104

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

19380

Chester County Hospital, West Chester

35233

University of Alabama, Birmingham

63110

Washington University School of Medicine, St Louis

190467

Montefiore Medical Center, The Bronx

02115

The Brigham and Women's Hospital, Boston

08901

Rutger's University / Cancer Institute of New Jersey, New Brunswick

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT04305613 - Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy | Biotech Hunter | Biotech Hunter